Selank and Immune Function Research: Anxiolytic Peptide Immunomodulation, T-Cell Biology and Cytokine Regulation Mechanisms UK 2026

This article is intended for researchers and laboratory professionals. All peptides discussed are for research use only (RUO) and are not approved for human administration, therapeutic use, or clinical application. PeptidesLab UK supplies research-grade Selank for in vitro and in vivo laboratory investigations only.

Selank and Immunomodulation: Tuftsin Analogue Biology at the Neuroimmune Interface

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 7 amino acids, MW 751 Da) is a synthetic analogue of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg, a fragment of the IgG heavy chain Fc region released by splenic leucosinase and serum carboxypeptidase). The Pro-Gly-Pro C-terminal extension confers protease resistance relative to native tuftsin, extending the biological half-life from ~2-3 minutes to ~10-20 minutes while retaining and enhancing tuftsin’s receptor-engaging pharmacophore. Selank’s primary immunological research context involves its bidirectional immunomodulatory profile — enhancing immune surveillance and cytokine production under basal or immunosuppressed conditions while moderating excessive inflammatory responses — a duality that reflects tuftsin receptor (tuftsin receptor, putatively related to neuropeptide/opiate receptor family on phagocytic cells) and additional receptor interactions yet to be fully characterised.

The neuroimmune intersection positions Selank uniquely: as an anxiolytic/nootropic peptide modulating GABAergic, serotonergic, and BDNF pathways in the CNS while simultaneously exerting immunomodulatory effects on peripheral lymphocytes and macrophages through both direct receptor engagement and indirect neuroendocrine (HPA axis, sympathetic) pathways. This dual CNS-immune biology makes Selank valuable for research in the neuroscience of immune dysregulation (stress immunosuppression, psychoneuroimmunology) as well as direct cellular immunology.

T-Cell Biology: Proliferation, Th1/Th2 Balance and Regulatory T-Cell Research

Primary T-cell immunology research with Selank employs human peripheral blood mononuclear cells (PBMC, Ficoll-Hypaque density gradient, Lymphoprep, 400g 30 min, buffy coat harvest, >95% viability Trypan Blue), murine splenic T cells (nylon wool column enrichment or CD3+ MACS positive selection, ≥90% purity), and specific T-cell subsets (CD4+, CD8+ by MACS separation). Polyclonal T-cell activation: ConA (2.5 μg/mL murine spleen) or anti-CD3/CD28 antibody coated beads (Dynabeads Human T-Activator, 1:1 bead:cell ratio) ± Selank (0.1-1000 ng/mL, concentration range spanning physiological to pharmacological) for 48-72h.

Proliferation endpoints: [³H]-thymidine incorporation (1 μCi/well for final 18h, liquid scintillation, CPM); CFSE dilution flow cytometry (CFSE 5 μM, 37°C 10 min labelling, violet laser 405 nm/450-50 nm BP, division index and generation analysis by FlowJo v10 Proliferation model); BrdU ELISA (Roche Cell Proliferation ELISA, BrdU, 4h pulse, OD370-OD492). Selank dose-response in low-dose ConA (1 μg/mL, sub-optimal activation) versus high-dose ConA (5 μg/mL, maximal activation) reveals context-dependent effects: at sub-optimal activation, Selank (10-100 ng/mL) enhances proliferation; at maximal activation, Selank reduces hyper-proliferation toward normal — the bidirectional immunomodulatory signature characteristic of tuftsin-family peptides.

Th1/Th2/Th17 cytokine profiling: intracellular cytokine staining (ICS) by flow cytometry — CD4+ T cells stimulated with PMA (50 ng/mL) + ionomycin (500 ng/mL, 4h) + brefeldin-A (BFA, 10 μg/mL, final 2h) → fix/perm (BD Cytofix/Cytoperm kit) → anti-IFN-γ PE (Th1), anti-IL-4 APC (Th2), anti-IL-17A PerCP-Cy5.5 (Th17), anti-IL-2 FITC (activation) — with Selank pre-treatment (24h, 10-100 ng/mL) modifying the Th1:Th2 balance, typically normalising toward Th1 dominance in allergic/atopic models and toward Th2 in autoimmune-primed models. Luminex multiplex (Human Cytokine 17-plex or murine equivalent: IFN-γ, IL-4, IL-5, IL-10, IL-13, IL-17A, IL-2, TNF-α, IL-6, IL-12p70, MCP-1, IL-1β, IL-8/CXCL8, RANTES, IP-10, G-CSF, GM-CSF) in culture supernatants at 24h and 72h provides the full cytokine landscape.

Regulatory T-Cell Research: FoxP3+ Treg Induction and Immune Tolerance

Regulatory T cells (Tregs, CD4+CD25+FoxP3+) are central mediators of peripheral immune tolerance and anti-inflammatory homeostasis. Selank’s putative IL-10-inducing and TGF-β1-promoting properties position it as a candidate modulator of Treg biology. Research protocols: sorted CD4+CD25- conventional T cells (MACS depletion of CD25+ then positive selection CD4+, purity ≥95%) cultured with TGF-β1 (5 ng/mL) + IL-2 (100 IU/mL) ± Selank (10-100 ng/mL) for 5 days to induce peripherally-derived Treg (pTreg) conversion — FoxP3 expression by intranuclear staining (anti-FoxP3 PE, clone PCH101, eBioscience, Fix/Perm Foxp3 buffer set) flow cytometry.

Treg suppressive capacity assay: sorted CD4+CD25+CD127low Tregs from Selank-treated PBMC cultures co-cultured with CFSE-labelled CD4+CD25- responder T cells (1:1, 1:4, 1:16 Treg:responder ratios) activated with anti-CD3/CD28 beads (1:4 bead:responder ratio) for 72h — % CFSE dilution by flow quantifies Treg suppressive capacity (% suppression = (CPM no Treg − CPM with Treg)/CPM no Treg × 100). Suppressive cytokines: IL-10 and TGF-β1 in Treg culture supernatants by ELISA (R&D Systems DY217B and DY1679) confirming the effector mechanism. Helios+FoxP3+ (natural Treg) versus Helios-FoxP3+ (peripherally induced pTreg) discrimination by flow (anti-Helios APC, clone 22F6, BioLegend) establishes whether Selank promotes thymic Treg survival versus peripheral conversion.

Macrophage Research: Phagocytosis, Oxidative Burst, and M1/M2 Polarisation

Tuftsin family peptides were originally characterised as macrophage-activating factors, stimulating phagocytosis and bactericidal activity. Selank’s macrophage immunology research employs: THP-1 cells (PMA 100 ng/mL, 48h differentiation to macrophage-like cells), J774A.1 murine macrophage cell line, and primary peritoneal macrophages (thioglycolate 3% Brewer’s modification, 3 mL i.p., 4-day harvest, PBS lavage, 10 mL, Trypan Blue count, plated 5×10⁵/well).

Phagocytosis: FITC-E. coli BioParticles (Invitrogen, 10:1 particle:cell, 37°C 1h) versus control 4°C (surface-bound only), quench with Trypan Blue (0.04%), flow cytometry FL1 FITC phagocytic index (% positive × MFI); IgG-opsonised sheep red blood cell (SRBC) phagocytosis by light microscopy count (erythrophagocytosis index, ≥3 SRBC/macrophage = phagocytic); fluorescent latex bead (1 μm FITC-latex, 10:1) confocal imaging for phagocytic cup formation (F-actin phalloidin, Draq5 nucleus) quality assessment. Selank (1-100 ng/mL, 30 min pre-treatment) dose-response confirms tuftsin-like phagocytic enhancement.

Oxidative burst: DHR-123 (dihydrorhodamine 123, 1 μM, 10 min pre-load) → PMA 100 ng/mL (30 min) or fMLP (1 μM, 15 min) → flow cytometry 488 nm excitation, FL1 rhodamine 123 fluorescence (% responders and MFI). Luminol-amplified chemiluminescence (luminol 5 μM + horseradish peroxidase, white 96-well plate, Spark luminometer, relative light units/s/10⁵ cells) provides a continuous real-time oxidative burst kinetic readout. Selank pre-treatment effect on PMA-stimulated oxidative burst establishes dose-dependent phagocyte activation or inhibition (bidirectional immunomodulation context-dependence).

M1/M2 polarisation: M1 (LPS 100 ng/mL + IFN-γ 20 ng/mL, 24h): CD80+CD86+MHC-II+ flow cytometry surface markers, TNF-α + IL-6 + IL-12p70 Luminex, iNOS mRNA qPCR and nitrite assay (Griess reagent, OD540). M2 (IL-4 20 ng/mL + IL-13 20 ng/mL, 48h): CD163+CD206+CD209+ flow markers, IL-10 + TGF-β1 ELISA, arginase-1 mRNA qPCR and activity (urea production, diacetylmonoxime, OD540). Selank (10-100 ng/mL) added to M1 polarisation protocol: shifts toward M2 markers confirming anti-inflammatory polarisation potential. M1:M2 ratio (CD86:CD206 MFI ratio, or IL-12:IL-10 cytokine ratio) as integrated polarisation index.

Stress Immunology Research: HPA Axis, Cortisol, and Selank’s Neuroimmune Bridge

Chronic stress produces immunosuppression through elevated cortisol (glucocorticoid receptor-mediated lymphocyte apoptosis, Th1→Th2 shift, NK cell suppression). Selank, as an anxiolytic peptide with HPA axis-modulating properties, bridges neuroimmune research: reducing perceived stress → reducing HPA activation → preserving immune competence. Murine chronic restraint stress (CRS) model (6h/day × 21 days) produces corticosterone elevation (ELISA, plasma ZT12 peak), thymic involution (thymus weight, CD4+CD8+ DP thymocyte % by flow), and impaired ConA-induced splenic T-cell proliferation (CFSE or [³H]-thymidine). Selank treatment (40-300 μg/kg i.n. or i.p., daily during CRS) with primary endpoints: (i) plasma corticosterone ELISA at days 7, 14, 21; (ii) CFSE T-cell proliferation ex vivo (splenic, ConA 2.5 μg/mL, 72h); (iii) splenic NK cell cytotoxicity (K562 calcein-AM, E:T 10:1-50:1, specific lysis %); (iv) splenic and thymic weight and histology (H&E, cortex:medullary ratio).

Mechanism dissection for stress neuroimmune effects: adrenalectomy (ADX) + corticosterone replacement (pellet, physiological 25 μg/day, or stress-level 250 μg/day, 90-day release) separates HPA-corticosterone-dependent from direct Selank autonomic effects on immune function. Propranolol (β-adrenergic blockade, 5 mg/kg s.c.) before CRS or Selank treatment assesses the sympathetic nervous system arm. GR (glucocorticoid receptor) antagonist mifepristone (RU-486, 10 mg/kg i.p. daily) during CRS with and without Selank isolates corticosterone-GR effects from direct Selank-immune effects. These three pharmacological dissections (ADX, propranolol, mifepristone) provide the neuroimmune mechanistic framework linking Selank’s CNS anxiolytic effect to peripheral immune preservation.

Enkephalinase and Peptidase Research: Met-Enkephalin and Endogenous Ligand Interactions

Selank has been reported to inhibit enkephalin-degrading peptidases (enkephalinase/neprilysin, CD10, and dipeptidyl peptidase IV/DPIV), potentially increasing endogenous Met-enkephalin and Leu-enkephalin half-lives. Met-enkephalin (Tyr-Gly-Gly-Phe-Met) interacts with δ-opioid receptors on lymphocytes and NK cells, enhancing NK cytotoxicity and T-cell proliferation at physiological concentrations. Research on this indirect mechanism: (i) enkephalinase activity assay — fluorometric substrate Aβ(4-22)amide or Abz-Ala-Gly-Leu-pNA (OD410, nmol substrate hydrolysed/min/mg protein in PBMC membrane fraction) with Selank (0.1-100 nM) concentration-dependent inhibition; (ii) Met-enkephalin ELISA (Peninsula Laboratories RIK-063-01) in PBMC conditioned medium before and after Selank treatment confirming elevated endogenous enkephalin; (iii) δ-opioid receptor antagonist NTII (naltrindole, 10 μM) block of Selank-enhanced NK cytotoxicity confirming opioid receptor mediation of the indirect immunostimulatory pathway.

Control Design and Research Rigour

Rigorous Selank immune research requires: (i) tuftsin comparison — native tuftsin (Thr-Lys-Pro-Arg) at equimolar concentrations as the pharmacophore comparator, with stability controls showing Selank’s longer biological persistence; (ii) peptidase controls — heat-inactivated Selank (95°C, 10 min) and scrambled Selank as negative controls confirming sequence- and structure-specific effects; (iii) endotoxin validation — LPS contamination mimics macrophage immunostimulation and confounds phagocytosis/oxidative burst assays; Selank must be ≥98% HPLC purity, endotoxin ≤0.1 EU/mg (lower threshold than standard given macrophage LPS sensitivity), LAL assay on every lot; (iv) donor variability — human PBMC research requires minimum n=8 donors with mixed sex, age-matched cohorts and exclusion criteria (no immunosuppressants, no acute illness); (v) cytokine assay timing — Luminex cytokine peaks differ: TNF-α at 4-6h, IL-6 at 12-24h, IL-10 at 24-48h, requiring time-course sampling not single-timepoint; (vi) opioid receptor controls — naloxone (broad opioid antagonist, 10 μM) and NTII (δ-selective) to dissect enkephalinase-indirect from direct receptor effects; (vii) sex stratification — immune responses differ significantly by sex, requiring sex-stratified PBMC donor pools and in vivo cohorts.